Rinvoq approval bolsters AbbVie's autoimmune portfolio

With Humira adalimumab set to face increasing biosimilar competition internationally this year, AbbVie has notched its second U.S. regulatory win for a successor to its primary revenue driver with FDA’s approval Rinvoq upadacitinib on Friday for rheumatoid arthritis.